Trial Profile
A Single-center, Double-blind, Placebo-controlled, Randomized Study to Investigate the Tolerability, Safety, Pharmacokinetics, and Pharmacodynamics of Single- and Multiple-dose ACT-541468 in Healthy Japanese and Caucasian Subjects
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 12 Mar 2020
Price :
$35
*
At a glance
- Drugs Daridorexant (Primary)
- Indications Insomnia
- Focus Pharmacokinetics
- Sponsors Actelion Pharmaceuticals
- 01 Mar 2020 Results published in the Journal of Clinical Psychopharmacology
- 12 Jun 2019 According to an Idorsia Pharmaceuticals media release, results from this study assessing the effect of ACT-541468 in Japanese and Caucasian volunteers were presented at the SLEEP 2019 (in San Antonio, Texas, USA).
- 26 Apr 2017 Status changed from active, no longer recruiting to completed.